List of Sunosi drug patents

Sunosi is owned by Jazz.

Sunosi contains Solriamfetol Hydrochloride.

Sunosi has a total of 9 drug patents out of which 0 drug patents have expired.

Sunosi was authorised for market use on 17 June, 2019.

Sunosi is available in tablet;oral dosage forms.

Sunosi can be used as to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa), to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily, treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment, treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily.

Drug patent challenges can be filed against Sunosi from June, 2023.

The generics of Sunosi are possible to be released after 19 March, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877806 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US9604917 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US10351517 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US8440715 JAZZ Treatment of sleep-wake disorders
Aug, 2027

(4 years from now)

US10512609 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10195151 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10912754 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(15 years from now)

US10959976 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(15 years from now)

US10940133 JAZZ Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment

Dosage: TABLET;ORAL

More Information on Dosage

Sunosi is owned by Axsome Malta.

Sunosi contains Solriamfetol Hydrochloride.

Sunosi has a total of 1 drug patent out of which 0 drug patents have expired.

Sunosi was authorised for market use on 17 June, 2019.

Sunosi is available in tablet;oral dosage forms.

Drug patent challenges can be filed against Sunosi from June, 2023.

The generics of Sunosi are possible to be released after 05 November, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic